Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Equal-Weight and lowers the price target ...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 pric...
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(...
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company s...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a $50 million milestone payment was received from Royalty Pharma ...
- Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertr...
